A Multi-centre, Open-label, Clinical, Phase 4 Trial, Following on From a Head-to-head Comparison Study of Two H1N1 Influenza Vaccines in Children, to Compare Firstly, the Persistence of Antibody Against the A/California/7/2009 (H1N1) Virus and Secondly the Immunogenicity and Reactogenicity of One Dose of a Non-adjuvanted Trivalent Seasonal Influenza Vaccine, in Children Who Had Received a Two-dose Immunisation Regimen of Celvapan or Pandemrix [EXTENSION OF 700049169]
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Influenza virus vaccine (Primary)
- Indications Influenza A virus H1N1 subtype
- Focus Adverse reactions; Biomarker; Pharmacodynamics; Pharmacogenomic
- 15 Feb 2013 New trial record